Latest studies
- RecruitingPHASE3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
This study looks at a daily tablet called upadacitinib for severe alopecia areata, a condition where your immune system attacks hair follicles, causing hair loss. It aims to see how safe and effective it is for teenagers and adults.
Alopecia AreataCroatia - RecruitingPHASE3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaCroatia - RecruitingPHASE2
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study looks at whether a new medicine, BI 764198, can help adults and teenagers with certain kidney problems. It compares the new medicine to a dummy pill to see if it reduces protein in the urine and improves kidney health.
Proteinuric Kidney DiseasesCroatia - RecruitingPHASE2
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
This study is testing a new medicine, efgartigimod, for adults with systemic sclerosis. It aims to see if the medicine helps improve symptoms and if it's safe, compared to a dummy medicine. We're looking for people to join for about 15 months.
Systemic Sclerosis (SSc)Croatia - RecruitingPHASE3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This study is looking at a new drug, camizestrant, for people with a common type of early breast cancer. It aims to see if camizestrant, compared to usual hormone therapy, can better prevent the cancer from coming back.
Breast Cancer, Early Breast CancerCroatia - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisCroatia - RecruitingPHASE4
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study looks at the long-term safety of a medicine called pirtobrutinib for people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It's for those already taking part in a previous pirtobrutinib study, to continue treatment and monitoring.
Chronic Lymphocytic LeukemiaLymphoma, Small LymphocyticCroatia - Active not recruitingPHASE2
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
This study is looking into a new medication called ESK-001 for adults with an active form of lupus (SLE). We want to see if it's safe and helps improve symptoms compared to a dummy drug (placebo).
SLECroatia - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionCroatia - RecruitingPHASE3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
This study looks at new treatments, CagriSema and cagrilintide, for children and teenagers aged 8-18 who are overweight. It compares these new drugs to an existing medicine (semaglutide) or a dummy drug (placebo) to see how well they help with weight loss.
OverweightObesityCroatia - Ongoing, recruitingTherapeutic use (Phase IV)
An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa
This study looks at how well different medicines (Elcocta and Alprolix) help people with haemophilia A or B protect their joints. Researchers will follow participants for 18 months to see if these treatments prevent joint problems.
Hemophilia A and BCroatia - RecruitingPHASE3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
This study looks at a new drug called Tralokinumab for children and babies with moderate to severe eczema. We want to see if it's safe and helps when given with standard eczema creams. It could offer new hope for managing this condition.
Atopic DermatitisCroatia - Active not recruiting
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
This study looks at how well a medicine called Humira works and how safe it is for children aged 6 to 17 with Crohn's disease. It also compares Humira to other common treatments like azathioprine, 6-mercaptopurine, or methotrexate, watching patients over a long time.
Crohn's DiseaseCroatia - Active not recruitingPHASE3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
This study compares a new drug, cabozantinib, with a dummy drug (placebo) for differentiated thyroid cancer that has continued to grow despite previous treatments. It aims to see if cabozantinib can slow down the cancer's progression.
Differentiated Thyroid CancerCroatia - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisCroatia - Enrolling by invitationPHASE3
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
This study looks at the long-term effects and safety of a drug called Ralinepag for people with a lung condition called pulmonary arterial hypertension (PAH). It's for those who have already tried Ralinepag in a previous study.
PAHPulmonary HypertensionPulmonary Arterial HypertensionHypertensionCroatia - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaCroatia - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesCroatia - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
Systemic Lupus ErythematosusCroatia - Active not recruitingPHASE3
A Study of Zigakibart in Adults With IgA Nephropathy
This study is testing a new medicine, BION-1301, for adults with IgA Nephropathy to see if it can help their kidneys. It compares the new medicine to a dummy medicine (placebo).
IgA NephropathyImmunoglobulin A NephropathyCroatia - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseCroatia - Active not recruiting
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This study looks at the long-term effects of a medicine called Humira for adults with a bowel condition called ulcerative colitis. It aims to see how well Humira works and if it's safe over a long time when used as doctors usually prescribe it.
Ulcerative Colitis (UC)Croatia - Active not recruitingPHASE3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
This study is looking at a new medicine called remibrutinib for people with relapsing multiple sclerosis (RMS). It compares remibrutinib to an existing medicine, teriflunomide, to see how well it works and if it's safe. It's a large study, involving about 800 people.
Relapsing Multiple SclerosisCroatia - Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Gaucher disease over time, whether or not they are receiving treatment. There's also a sub-study for pregnant women with Gaucher disease to see how their pregnancies and babies' health progress. It helps doctors learn more about the condition.
Gaucher DiseaseCerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency DiseaseGlucosylceramide Beta-Glucosidase Deficiency DiseaseCroatia - RecruitingPHASE3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This study looks at the long-term safety of a new medicine, KarXT, for people with changes in their thoughts and feelings due to Alzheimer's disease. Participants have already taken part in similar studies and will continue to be monitored for about a year.
Psychosis Associated With Alzheimer's DiseaseCroatia - Enrolling by invitationPHASE1
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
This study is looking at a new treatment called RAY121 for people with certain immune conditions like lupus-like disorders, skin blistering, or blood problems. It's a long-term follow-up for people who did well in an earlier study, to see how RAY121 works over time and if it continues to help.
Antiphospholipid Syndrome (APS)Bullous Pemphigoid (BP)Behçet's Syndrome (BS)Dermatomyositis (DM)Croatia - Active not recruitingPHASE3
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
This study compares a new drug combination (enfortumab vedotin plus pembrolizumab) with standard chemotherapy for bladder cancer that has spread to the muscle. It aims to see if the new combination, given before surgery, works better and is safe.
Bladder CancerCroatia - Active not recruitingPHASE3
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
This study is testing a new injection, Plozasiran, for adults with very high triglycerides. It will check if the treatment is safe and effective compared to a dummy injection over 12 months. Afterwards, participants might continue in an optional extension.
Severe HypertriglyceridemiaCroatia - RecruitingPHASE3
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
This study looks at a new medicine called roxadustat for children and teenagers with kidney disease and low red blood cells (anemia). It's a pill, hoping to be a new way to treat this condition instead of injections.
Chronic Kidney DiseaseRenal AnemiaCroatia - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisCroatia - RecruitingPHASE3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
This study looks at a new medicine called felzartamab for adults with a kidney disease called IgA nephropathy (IgAN). Researchers want to see if it reduces protein in the urine and helps kidney function. It involves infusions and careful monitoring.
Immunoglobulin A Nephropathy (IgAN)Croatia - Recruiting
Trifecta-Kidney cfDNA-MMDx Study
This study looks at new ways to check for rejection in kidney transplant patients. It compares a new blood test (DD-cfDNA) with a special biopsy test (MMDx) and traditional checks to see which is best at finding rejection accurately.
Kidney Transplant RejectionCroatia - AuthorisedTherapeutic confirmatory (Phase III)
A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy
This study is looking at a new medicine called zigakibart for adults with a kidney condition called IgA nephropathy. It will check if the medicine is safe and how well people tolerate it over a long time, as well as its effects on kidney health.
IgA nephropathyCroatia - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This study looks at the everyday safety and how well a drug called tolebrutinib is tolerated over a long time. It's for adults with different types of multiple sclerosis (MS) who have already been in earlier tolebrutinib studies.
Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple SclerosisCroatia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
This study is looking into a new medicine, Zasocitinib, for people with psoriatic arthritis. It's checking its long-term safety and how well it helps their symptoms. Participants will either get Zasocitinib or a dummy medicine.
Psoriatic ArthritisCroatia - Active not recruiting
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
This study looks at the long-term effects of ADYNOVI/ADYNOVATE medicine for people with haemophilia A. Researchers want to see how it works and if there are any side effects when used in everyday life.
Hemophilia ACroatia - Active not recruiting
Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment
This study looks at how safe and effective a new device called Silk Vista or Silk Vista Baby is. It's used to treat weak spots in blood vessels in the brain, called aneurysms, which could burst. Doctors will observe patients who are already having this treatment.
Intracranial AneurysmFlow DiverterCroatia - Active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
This study compares two medicines, entrectinib and crizotinib, for advanced lung cancer (non-small cell lung cancer) that has a specific genetic change called ROS1. It aims to see which medicine works better and is safer for patients, including those whose cancer has spread to the brain.
Carcinoma, Non-Small-Cell LungCroatia - Active not recruitingPHASE3
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
This study is testing a new medicine, barzolvolimab, for people with chronic spontaneous urticaria (CSU), also known as chronic hives. It aims to see if the medicine is safe and helps reduce hives better than a dummy medicine (placebo) for those whose current treatments aren't enough.
Chronic Spontaneous UrticariaCroatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (PD-1 antagonist) and chemotherapy.
This study is testing a new combination of treatments for advanced lung cancer. It combines a new drug, eftilagimod alfa, with existing treatments like pembrolizumab and chemotherapy, to see if it can help people live longer and improve their quality of life. Participants will be randomly assigned to different treatment groups.
Advanced/metastatic non-small cell lung cancer (NSCLC)Croatia - Active not recruitingPHASE3
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study looks at a new drug, Pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares Pirtobrutinib to standard treatments to see if it works better for those who have already tried other therapies.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCroatia - RecruitingPHASE3
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
This study is testing a medicine called OCTAPLEX for people experiencing serious bleeding while taking a specific type of blood thinner (Factor Xa inhibitor). Researchers want to see if OCTAPLEX can effectively stop the bleeding and if it's safe, comparing two different doses.
Acute Major BleedingCroatia - Active not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
This study looks at how well certain eye medicines from Roche work for conditions like wet macular degeneration and diabetic eye disease in real patients. It's about understanding long-term results and why doctors choose specific treatments, without changing how patients are usually cared for.
Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein OcclusionBranch Retinal Vein OcclusionCroatia - RecruitingPHASE3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
This study is testing a new medicine, XEN1101, for people with focal-onset seizures to see if it helps reduce seizures and is safe. Some people will get the real medicine, and others a dummy pill. It's for adults (18+) who already take seizure medicine.
Focal Onset SeizuresCroatia - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study looks at the long-term safety and effectiveness of a medicine called Upadacitinib for people with ulcerative colitis. It's for those who haven't fully responded to previous treatment or have completed an earlier study.
Ulcerative Colitis (UC)Croatia - Active not recruitingPHASE4
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
This study looks at two different doses of a drug called cabozantinib for a type of thyroid cancer called medullary thyroid cancer (MTC) that has spread and is getting worse. We want to see if a lower dose works just as well with fewer side effects.
Medullary Thyroid CancerCroatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients ≥12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; efanesoctocog alfa) for 24 months
This study is looking at a new treatment called efanesoctocog alfa for severe haemophilia A. It aims to see how it affects physical activity and joint health in patients aged 12 and over, comparing results over 24 months. It's a key step in understanding if this medicine helps people live more active lives.
Haemophilia ACroatia - RecruitingPHASE3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
This study is looking for better ways to treat advanced kidney cancer that has come back after earlier treatment. Researchers want to see if a new combination of medicines, belzutifan and zanzalintinib, works better than a standard medicine, cabozantinib, at shrinking the cancer.
Renal Cell CarcinomaCroatia - RecruitingPHASE2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It aims to see if the medicine is safe and helps improve symptoms compared to a dummy pill. It's a pill taken by mouth.
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active SevereCroatia - RecruitingPHASE3
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
This study is looking at a new medicine called filgotinib for children and teenagers aged 8 to 18 with moderate to severe ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, compared to what we already know about its use in adults.
Ulcerative ColitisCroatia